Stock EYEN EYENOVIA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Eyenovia, Inc.

Equities

EYEN

US30234E1047

Delayed Nasdaq
Other stock markets
 12:24:07 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.7043 USD +12.11% Intraday chart for Eyenovia, Inc. +36.36% -66.14%
Apr. 25 Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension CI
Apr. 08 Eyenovia to Weigh Potential Sale, Other Strategic Alternatives MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives
Eyenovia Explores Wide Range of Strategic Alternatives
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
Eyenovia Reports FDA Approval for Formosa's Post-Op Eye Inflammation, Pain Treatment
US FDA approves Eyenovia's eye drug, Formosa Pharma says
Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Eyenovia, Inc. Appoints Michael Geltzeiler to Serve on the Board and as the Chair of the Audit Committee of the Board
Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
Eyenovia Prices $12 Million Registered Direct Offering
Insider Buy: Eyenovia
Eyenovia Acquires US Rights to Eye Surgery Drug From Formosa
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of App13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
Eyenovia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Eyenovia, Inc. Announces First Commercial Sale of Mydcombi
Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Eyenovia Gets FDA Approval for Mydcombi Ophthalmic Spray; Shares Fall
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EYEN Stock
  4. News Eyenovia, Inc.
  5. Other languages